Interleukin-8 (IL-8), a chemokine implicated in the metastasis and angiogenesis of a variety of cancers, has been reported to be overexpressed in prostate cancer. In this study, we ascribe a new role for IL-8 in prostate cancer progression using LNCaP cells. We demonstrate that IL-8 activates the androgen receptor and confers androgen-independent growth, while serving as a potent chemotactic factor. Our evaluation of the possible signal pathways involved in androgen-independence and cell migration shows that the tyrosine kinases Src and FAK (focal adhesion kinase) are involved in IL-8-induced signaling. Pharmacological and genetic inhibitors of Src and FAK interfere with IL-8-induced cell migration, while only the Src inhibitor was able to repress androgenindependent growth. This suggests that both growth and migration depend on the activity of Src, whereas cell migration also requires the activation of FAK. Our evidence that IL-8-induced androgen-independent growth is, at least in part, due to androgen receptor activation includes (1) an inhibitor of androgen receptor activity diminishes cell growth; (2) androgen receptor transactivation potential is augmented by IL-8 and (3) androgen receptor is recruited to the promoter of prostate specific antigen (PSA) upon IL-8 treatment, based on chromatin immunoprecipitation experiments. Taken together, our data suggest that in addition to its role in metastasis and angiogenesis, IL-8 may also serve as a facilitator for androgen-independent transition of prostate cancers. To our knowledge, this is the first report about the tyrosine kinase signals and androgen receptor activation induced by IL-8 in prostate cancer cells. The observation that IL-8 mediates its growth and chemotactic effects via Src and FAK suggests the potential use for tyrosine kinase inhibitors at early stage of prostate cancer development.
Introduction
Prostate cancer is the most common malignancy found in American men and is the second leading cause of cancer-related mortality in the US. The current treatment for prostate cancer includes androgen ablation and anti-androgen therapy. These treatments are generally not curative and are only effective for early stages of prostate cancer, with an eventual outgrowth of androgen-refractory and metastatic tumor. Understanding the genetic or epigenetic factors that facilitate the transition from androgen-dependent to independent state is crucial in the design of future interventional strategies. Peptide growth factors (i.e. EGF, KGF and IGF1) and growth factor receptors (i.e. erbB2/HER2) have been shown to induce androgen receptor activation or androgenindependent growth of prostate cancer cells (Culig et al., 1994; Craft et al., 1999; Yeh et al., 1999; Torring et al., 2000; Wen et al., 2000; Shi et al., 2001) . Cytokines and neuropeptides including Interleukin-6 (IL-6), bombesin/GRP and neurotensin have also been implicated in this process and can activate androgen receptor in the absence of ligand (Chen et al., 2000; Lee et al., 2001; Dai et al., 2002; Debes et al., 2002; Ueda et al., 2002; Lee et al., 2003) . These factors are associated with different signal pathways and the mechanisms underlying androgen independence are likely to be multiple. One interesting common thread among the above factors is the activation of tyrosine kinases. ErbB2/HER2 and the receptors associated with IGF, KGF and EGF are all tyrosine kinases. IL-6 is known to activate erbB2/HER2 and JAK family of tyrosine kinases through the gp130 receptor, with the subsequent activation of MAPK and STATs (Qiu et al., 1998; Chen et al., 2000; Yang et al., 2003) . Likewise, neuropeptides that engage the Gprotein-coupled receptors also activate nonreceptor tyrosine kinases, including Etk, Src and FAK and result in MAPK activation (Salazar and Rozengurt, 1999; Lee et al., 2001; Hunger-Glaser et al., 2003; Xiao et al., 2003) . Several studies have demonstrated that serine/ threonine kinases such as MAPK and AKT can phosphorylate and modulate the androgen receptor, providing a plausible mechanism whereby androgen receptor can be activated in a ligand-independent manner (Yeh et al., 1999; Wen et al., 2000; Lin et al., 2001; Gioeli et al., 2002) .
Other studies aimed at uncovering factors involved in the angiogensis, invasion and metastasis of prostate cancer cells have identified VEGF, IL-8 and bFGF as major contributors (Ferrer et al., 1998; Balbay et al., 1999) . IL-8 is a CXC chemokine, initially identified as a regulator for the recruitment and trafficking of leukocytes to sites of inflammation (Matsushima et al., 1992; Onuffer and Horuk, 2002) . Subsequent studies demonstrated that IL-8 is a common chemotactic factor, involved in the migration and invasion of cancer cells. Prostate cancer cells have been shown to express and secrete high levels of interleukin-8 (in PC3) and its related chemokine GROa (in DU-145) (Moore et al., 1999; Reiland et al., 1999) as well as the IL-8 receptors, CXCR1 and CXCR2 (Reiland et al., 1999) . The serum level of IL-8 has been shown to correlate with the development of prostate cancer and is a potential independent predictor of the disease . Transfection of sense and antisense constructs of IL-8 clearly demonstrated its importance in the growth and invasive properties of the prostate cancer cell line PC3 (Inoue et al., 2000) . The selection for androgen refractory prostate cancer cell lines (CL1-GFP) resulted in an increased expression of IL-8 compared to parental LNCaP (Patel et al., 2000) . Although there is considerable information regarding the role of IL-8 in metastasis and invasion of prostate cancer cells (Greene et al., 1997; Ferrer et al., 1998; Inoue et al., 2000; Patel et al., 2000) , very little is known about the signal pathways involved in these biological processes. Furthermore, given the high expression of IL-8 during a premetastatic cancer stage, we asked whether IL-8 can play an additional role in the development of androgen-independent prostate cancer.
We report here that, in addition to being a potent chemotactic factor, IL-8 is able to activate androgen receptor and confer androgen-independent growth of LNCaP cells through the activation of Src. We also show that IL-8 can activate FAK tyrosine kinase to induce chemotaxis and cell migration in LNCaP cells. This study adds to our current knowledge of the signal pathways mediated by IL-8 and demonstrates for the first time that IL-8 may serve as a progression factor involved in androgen-independent growth of prostate cancer cells.
Results

IL-8 induces androgen-independent growth of LNCaP
To determine if IL-8 is involved in androgen-independence transition process, we measured the effects of IL-8 on the growth of the androgen-dependent prostate cancer cell line, LNCaP, after hormone depletion. Under androgen-deprived conditions, LNCaP cells grow only marginally (Figure 1a ). The addition of 10 nM IL-8 significantly increased the growth of LNCaP cells, albeit with less potency than synthetic androgen R1881. To determine whether IL-8 induces androgenindependent cell growth in a dose-dependent manner, LNCaP cells were treated with varying concentration of IL-8 (0-100 nM). The results showed that the growth stimulation by IL-8 is dose dependent and that this induction was observed with a concentration of IL-8 as low as 1 nM (Figure 1b) , a level that is commonly detected in patients' tumor samples. The growth induction of LNCaP by IL-8 reaches a maximum at 100 nM. Taken together, these data show that IL-8 can induce androgen-independent growth of LNCaP cells.
IL-8-induced androgen independence involves androgen receptor
Mechanistically, there are two ways by which IL-8 can induce androgen-independent growth of LNCaPs. IL-8 can activate a growth pathway that completely bypasses androgen and androgen receptor activation. Alternatively, IL-8 can activate the androgen receptor in the absence of androgen, and utilize the existing androgen receptor pathway to induce growth. To ascertain the involvement of androgen receptor, the anti-androgen bicalutamide (casodex), which inactivates the transactivation potential of androgen receptor, was included in the media. If IL-8-induced growth requires active androgen receptor, the growth of LNCaP should be compromised by the addition of bicalutamide. As illustrated in Figure 2a , bicalutamide significantly inhibited IL-8-induced cell growth, indicating the participation of androgen receptor in this process. To further demonstrate that androgen receptor is activated by IL-8, a plasmid carrying a luciferase reporter gene driven by androgen responsive element (ARE) was constructed and introduced into LNCaP cells, followed by treatment with IL-8. As shown (Figure 2b ), IL-8 induces the expression of ARE-Luc in the absence of androgen, and this induction is blocked by casodex.
These results suggest that IL-8 is able to activate androgen receptor and in so doing, contributes at least in part to androgen-independent growth of LNCaP. If androgen receptor is affected by IL-8 treatment, we reasoned that androgen receptor should be recruited to an ARE site of PSA promoter after IL-8 treatment.
Using a chromatin immunoprecipitation approach we recently described (Louie et al., 2003) , we monitored the movement of androgen receptor upon IL-8 treatment.
As shown in Figure 2c upper panel, 0.5 h after IL-8 treatment, androgen receptor is seen to occupy the ARE site of the PSA promoter, and this occupancy persists at 2 h after treatment. In contrast, no recruitment of androgen receptor to an adjacent upstream region lacking ARE sequence was found (Figure 2c ). These data, taken together, provide the first evidence that IL-8 is able to modulate the activity of androgen receptor.
The role of Src and FAK tyrosine kinases in IL-8-mediated androgen-independent growth
Using the tyrosine kinase display approach we developed earlier, we were able to obtain the entire tyrosine kinase expression profiles for LNCaP cells (Robinson et al., 1996; Xia et al., 2002) . Among the tyrosine kinases tested (based on their tyrosyl-phosphorylation status), two kinases that show prominent activation by IL-8 are Src and FAK (Figure 3a) . Although the activation of Src-family kinases by certain G-protein-coupled receptors has been reported (Venkatakrishnan et al., 2000; Luttrell and Lefkowitz, 2002) , to our knowledge, this is the first report which shows that Src and FAK are activated by IL-8. Since IL-8 can activate Src kinase, we decided to test whether the IL-8-induced proliferation of LNCaP is mediated through the Src kinase pathway. LNCaP cells maintained in hormone-deprived medium were treated with 100 nM of PP2, a selective inhibitor of Src, prior to exposure to IL-8 or to R1881. As shown in Figure 3b , PP2 completely inhibited the growth induced by IL-8, whereas growth induced by R1881 was inhibited to a lesser extent, decreasing only 27%. This suggests that Src activation is critical in IL-8-induced growth. The slight inhibition of R1881-induced growth is consistent with a previous report that Src activation accompanies androgen treatment (Migliaccio et al., 2000) . An additional confirmation of the involvement of Src comes from transactivation analysis of an androgen receptor responsive promoter, using an Src dominant negative (DN) mutant ( Figure 3c ). We first confirmed the earlier experiment that IL-8 activates the transcription mediated by androgen receptor. We then included Src DN mutant, a kinase-dead construct, in which a lysine residue at the ATP binding pocket is mutated to an arginine residue. The Src DN mutant significantly downmodulated the transactivation potential of the androgen receptor. Taken together, these data suggest that Src tyrosine kinase may mediate the activation of androgen receptor by IL-8, leading to androgen-independent growth of LNCaP.
Next, we asked whether FAK tyrosine kinase activation is also necessary for IL-8-mediated androgen- Figure 2 IL-8-induced growth is mediated through the androgen receptor in an androgen-independent manner and androgen receptor is activated and recruited to the PSA promoter in response to IL-8. (a) LNCaP cells were hormone deprived for 3 days, pretreated with 5 mM Casodex and then treated with 10 nM IL-8. Proliferation was monitored using the MTT assay every other day. (b) Luciferase activity was assayed in LNCaP cells transiently transfected with the reporter plasmid ARE 5 -Luc followed by pretreatment with either 5 mM Casodex and then treatment with 10 nM IL-8. These results represent the average of two independent experiments and the error bars represent the s.d. (c) LNCaP cells were hormone deprived for 3 days and serum starved for 1 day prior to stimulation with 10 nM of IL-8. Protein-chromatin complexes were crosslinked with formaldehyde, sonicated, and immunoprecipitated with anti-AR. DNA fragments were purified and 10% of ChIP product or 1% of input was used in the PCR reactions. The top panel represents product from À39 to À255 bases upstream of the start site on the PSA promoter that spans the ARE I (À167 to À182) site. The lower panel represents product from À1993 to À2411 of the PSA promoter which does not contain an ARE site IL-8 confers androgen-independent growth and migration of LNCaP L-F Lee et al independent growth. For lack of a selective inhibitor of FAK, we decided to use a DN FAKDN-LNCaP cell line we previously established (Lee et al., 2001) , in which the overexpressed FAK carrying a mutation in tyrosine 397 was shown to have a decreased ability to phosphorylate and to form signal complex. The growth property was tested under androgen-deprived conditions, in the presence or absence of IL-8 treatment. IL-8 was able to promote the growth of FAKDN-LNCaP in a manner similar to the wild-type LNCaP, suggesting that FAK activation plays, if any, a minor role in IL-8-induced growth (Figure 3d ).
IL-8 increases cell migration of LNCaP
IL-8 is a known chemotactic factor for a variety of cell types (Onuffer and Horuk, 2002) . We wished to determine whether the migration of LNCaP cells is also affected by IL-8 stimulation. Different concentrations of IL-8 (0-10 nM) were added to the lower compartment of a modified Boyden chamber (see Material and methods). LNCaP cells were seeded in the upper chamber and allowed to migrate for 24 h. A dramatic 11-fold increase in the migration of LNCaP cells was observed with IL-8 at a concentration as low as 1 nM (Figure 4b ). The migration of cells was further increased to 13-fold at 10 nM of IL-8 (Figure 4a and b) .
Role of Src and FAK in IL-8-mediated cell migration
To determine whether Src and FAK are also involved in IL-8-mediated cell migration, a modified Boyden chamber assay was used to monitor the migration of LNCaP cells in the presence and absence of IL-8 and PP2. As shown in the left panel Figure 4c , IL-8 can induce LNCaP cell migration in serum-free media by 
IL-8 induced activation of ERK kinase
The finding that Src and FAK are involved in LNCaP motility in response to IL-8 is consistent with the well documented role of these two kinases in the phosphorylation of crucial substrates involved in focal adhesion and migration (Parsons et al., 2000) . However, it is less obvious as to how Src activation impacts androgenindependent growth and androgen receptor activation. Since effectors of Src kinases are serine/threonine kinases such as the MAPK family of kinases and AKT, we asked whether these kinases are activated by IL-8. Using phosphospecific antibodies, which detect the active form of ERK, JNK, p38 MAPK and AKT, we surveyed the activation status of these kinases in IL-8-treated LNCaP cells. We found, under our assay conditions, ERK is activated upon IL-8 addition (Figure 5a ). JNK, AKT and p38MAPK already had a relatively high basal phosphorylation level, which did not respond to IL-8 with any significant, further increase in phosphorylation. Since ERK is the only kinase tested that showed response to IL-8, we chose to focus on the role of ERK in IL-8-induced androgen-independent growth. PD98059, an inhibitor of the ERK pathway, was used to analyse whether ERK is involved in IL-8-induced growth in the absence of androgen. The results in Figure 5b showed that PD98059 significantly, but not completely, inhibited the IL-8-induced androgen-independent growth of LNCaP. Thus, IL-8-induced growth may involve multiple pathways, with the ERK pathway playing a prominent role.
Discussion
IL-8 is a chemokine well documented for its ability to induce chemotaxis and angiogenesis in a variety of tumor cell types including prostate cancer (Schadendorf et al., 1993; Xie et al., 1998; Miller et al., 1999; Xu et al., 2002) . There is considerable evidence that IL-8 is overexpressed in prostate cancer (Moore et al., 1999) . Recent studies using xenograft and cell line models strongly suggest that IL-8 is a progression factor for prostate cancer and inhibition of IL-8 expression results in inhibition of cell line and tumor growth (Inoue et al., 2000) . In this study, we ascribe a new role for IL-8 in prostate cancer progression, as a facilitator of androgenindependent growth of prostate cancer cells. Our view is that IL-8 is not the sole factor in rendering prostate cells androgen independent; likely additional genetic changes are also required. However, IL-8, like other growth factors and neuropeptides reported before (see below), may serve as an important mediator that prolongs the growth of androgen-dependent cells during androgen abalation therapy. Of relevance is a recent report showing that androgen suppresses the transcription of IL-8; the IL-8 production is expected to increase upon androgen withdrawal (Kanda and Watanabe, 2001 ).
How does IL-8 induce androgen independence? Based on the transactivation and the bicalutamide inhibitor data presented, it appears that activation of androgen receptor is involved. A number of growth factors (EGF, KGF, IGF1) (Culig et al., 1994) , cytokines (IL-6) (Chen et al., 2000; Debes et al., 2002; Ueda et al., 2002; Lee et al., 2003) and neuropeptides (GRP and neurotensin) (Lee et al., 2001; Dai et al., 2002) have been shown to be capable of activating androgen receptor in the absence of androgen. This work extends these studies and provides the first evidence for a chemokine to do so. The receptors for IL-8 are 7-transmembrane proteins coupled to Gai and Gaq family members. While the best understood response of this type of receptor is the activation of phospholipase C b with a consequent activation of PKC, tyrosine kinase activations have also been reported. IL-8 was shown to activate Hck, an Srclike kinase, in hematopoeitic cells (Barlic et al., 2000) . Most recently, Feniger-Barish et al. (2003) showed that the tyrosine kinase FAK was activated by IL-8 in rat basophilic leukemia cells. The present finding provides evidence that Src and FAK are coactivated by IL-8 and links it to the growth and migratory properties of prostate cancer cells. Additionally, we recently reported that bombesin, which engages a different type of G-protein-coupled receptor, is able to activate Src and FAK in LNCaP (Lee et al., 2001) . Thus, Src and FAK tyrosine kinases appear to play a significant role in transmitting signals emanating from tyrosine kinase receptors as well as G-protein-coupled receptors in prostate cancer cells. The present data also showed that Src activity is required for the enhanced androgen receptor activity and in sustaining androgen-independent growth of LNCaP. One of the major consequences of Src activation is the activation of ras/MEK/ERK pathway. ERK was shown to phosphorylate androgen receptor (Yeh et al., 1999) or its coactivator such as SRC-3/ACTR/AIB1 (Font de Mora and Brown, 2000) and in so doing, it has the potential to aid in the assembly of coactivator complex with androgen receptor, mimicking the ligand-bound state. Consistent with this hypothesis, we found ERK is activated in IL-8-treated LNCaP cells and an ERK inhibitor (PD98059) blocks IL-8-induced androgen-independent growth of LNCaP. It is however noteworthy that other serine/ threonine kinases such as AKT and p38MAPK, while not induced by IL-8, are already in active forms in LNCaP and may contribute to the androgen receptor activation as well. Concurrent with Src activation is FAK activation. FAK is known to be involved in cell motility and adhesion (Parsons et al., 2000) . This process requires a complex interaction of FAK with Src and p130cas as well as PI-3K (Chen and Guan, 1994; Cary et al., 1998; Sieg et al., 1999) . The phosphorylation of FAK by Src is important in attaining the full catalytic activity of FAK. The FAK DN mutant (Y397F) used in this study fails to bind Src (as well as PI-3 0 kinase), and is inactive in its catalytic activity (Chen and Guan, 1994) . We found that Src and FAK are both required for cell motility, consistent with the above model. Interestingly, the same FAK mutant does not diminish androgen-independent growth induced by IL-8. While this does not exclude FAK being involved in proliferation, it suggests that the signals activated by Src are sufficient to activate androgen receptor to promote cell growth. It is noteworthy that previous reports showed that FAK activity in LNCaP growing in regular medium was low (Tremblay et al., 1996; Sumitomo et al., 2000) . We showed in this and a previous study (Lee et al., 2001) that FAK is activated by IL-8 and neuropeptides, in androgen-deprived medium. Others showed that FAK can be activated in LNCaP under various conditions (Slack et al., 2001; Papakonstanti et al., 2003) . This suggests that FAK in LNCaP is not intrinsically defect; the lack of FAK activity in regular medium is likely due to the expression of androgen-induced inhibitors such as neutral endopeptidase (Sumitomo et al., 2000) .
At present, we do not know how IL-8-receptor activation leads to Src activation. If LNCaP behaves like other cell types, the recruitment by b-arrestin is one possible mechanism (Barlic et al., 2000) , and the direct activation by Gai is another (Ma et al., 2000) . A third possibility involves EGF receptor due to the posttranslational activation of HB-EGF by G-proteincoupled receptor (Prenzel et al., 1999) . Additional work is required to elucidate the mechanism of Src and FAK activation by IL-8.
In summary, the present study provides the following new information: (1) IL-8 is able to induce androgenindependent growth and migration of LNCaP and is the first chemokine to be shown with such a property; (2) IL-8 is able to activate androgen receptor based on transactivation and chromatin immunoprecipitation assays; (3) IL-8-induced androgen independence at least in part depends on androgen receptor activity, based on anti-androgen inhibition; and (4) IL-8 activates Src, FAK and ERK kinases to transmit growth and migratory signals and as such, specific inhibitors of these kinases may potentially be utilized in combination with androgen-ablation treatment regimens.
Materials and methods
Cells, antibodies and reagents
LNCaP cells (American Type Culture Collection, Rockville, MD, USA ) were maintained in RPMI 1640 medium with 10% fetal bovine serum (FBS). Human IL-8 was obtained from PeproTech Inc. (Rocky Hill, NJ, USA) and flutamide was obtained from Sigma. Bicalutamide (Astra-Zeneca) was a gift from Dr Xu Bao Shi, Cancer Center, UCD. PD98059 and pyrazolopyrimidine (PP2) were purchased from CalbiochemNovabiochem, Ltd. a-phosphotyrosine (4G10), a-FAK (rabbit), a-Src (GD11) and a-AR (PG-21) were purchased from Upstate Biotechnology Inc. (UBI) (Lake Placid, NY, USA).
Transfection and selection
LNCaP cells were transfected by using Effectene according to the manufacturer's instruction (Qiagen). The stable cell line LNCaP-FAKDN was created by transfection with HA-FAKY397F, a generous gift from Dr Junlin Guan (Cornell University, Ithaca). A pool of FAKDN-LNCaP cells were selected in G418 (600 mg/ml) containing media and the overexpression of the DN HA-FAKT397F was confirmed by Western blot analysis of total cell lysates by using a-HA antibody. Dominant negative Src (Src DN) (kindly provided by Dr June Zou, (UC Davis Cancer Center, CA, USA)) carries a mutation at the lysine of the ATP binding pocket and is kinase dead.
Cell proliferation assay
LNCaP cells were hormone deprived in RPMI 1640 containing 5% charcoal-dextran-stripped serum (CDS) for 48 h and 5000 cells were seeded per well in a 96-well plate. Following a 24 h incubation period, the cells were treated with varying concentrations of IL-8 (0-10 nM). Cell growth was monitored by MTT assay according to the manufacturer's protocol (Sigma). Proliferation assays in the presence of inhibitors, PP2, PD98059, flutamide and Casodex, were performed in a similar manner except that cells were pretreated with inhibitor 30 min prior to the addition of IL-8.
Cell migration assay
Cell migration was performed in 24-well microchambers using 8 mM pore size polyvinyl pyrrolidone-free polycarbonate filters (Nucleopore, Pleasanton, CA, USA). The lower wells of the microchamber were filled with varying concentrations of IL-8 in serum-free media containing 0.1% BSA. Cells (1 Â 10 5 ) in 500 ml of medium were added to the upper chamber. Each IL-8 concentration was run in triplicate, and cells were allowed to migrate for 4 or 24 h. Cells that migrated to the underside of the filter were stained with Diff-Quick (American Scientific Products, McGraw Park, IL, USA) and captured on a digital camera or counted as an average of five fields.
Immunoprecipitation and Western blot
LNCaP cells were serum starved for 48 h, followed by treatment with or without IL-8 (0.1 mg/ml). Immunoprecipitation and Western blot analysis were performed as described previously (Lee et al., 2001 ). a-Phosphotyrosine antibody (UBI) was used to detect tyrosine phosphorylation of FAK and Src. Equal levels of FAK and Src were confirmed by aÀFAK or aÀSrc, respectively. Chemiluminescence was performed using SuperSignal s (Pierce, Rockford, Ill.) according to the manufacturer's instructions. For the study of serine/ threonine kinase activation, antibodies against phospho-and total Erk1/2, JNK, p38MAPK and AKT from Cell Signaling (Beverly, MA, USA) were used for Western blot analysis.
Chromatin immunprecipitation
LNCaP cells were plated on 150 mm dishes and grown to 90% confluency, at which point they were hormone deprived in phenol-red-free RPMI 1640 supplemented with 5% CDS for 3 days followed by serum starvation overnight. Cells were treated for 2 h with DHT or for 30 min or 2 h with IL-8 or vehicle only before being crosslinked for 8 min with final concentration of 1% formaldehyde in 10 mM NaCl, 0.1 mM EDTA and 5 mM HEPES, pH 7.5. Cells were washed 2 Â with ice-cold PBS, harvested with a cell scraper and pelleted. Cell pellets were resuspended in ice-cold lysis-sonication buffer (10 mM EDTA, 50 mM Tris-HCl, pH 8, 0.5% SDS supplemented with Complete protease inhibitor cocktail (Roche) and 0.2 mg/ml AEBSF) and sonicated using a Macrotip at power 1.6, duty cycle 33%, for 30 pulses, three times with 2 min on ice between each cycle. Suspensions were diluted fivefold with icecold dilution buffer (150 mM NaCl, 2 mM EDTA, 20 mM TrisHCl, pH 8, 1% Triton X-100, Complete protease inhibitor cocktail, 0.2 mg/ml AEBSF) and 200 ml was removed for input control. Complexes were immunoprecipitated with a-AR DNA overnight at 41C, after which 2 mg sonicated salmon sperm was added and the immunocomplexes captured by adding protein A-sepharose 4B beads (Zymed) and incubating for 2 h at 41C. Beads were pelleted and resuspended in TSE (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl, pH 8) þ 150 mM NaCl. Beads were washed in succession with TSE þ 150 mM NaCl, then TSE þ 500 mM NaCl, then Buffer III (0.25 M LiCl, 1%NP-40, 1% NaDOC, 1 mM EDTA, 10 mM Tris-HCl, pH 8) and then TE. Complexes were eluted with 1%SDS, 0.1 M NaHCO 3 and reverse crosslinked at 651C overnight. Proteins were digested with Proteinase K for 1 h at 371C and the DNA fragments purified using the QIAquick PCR purification kit from Qiagen. In all, 10% of the ChIP product or 1% of the input control was used in each PCR reaction. PCR was performed using the following parameters: 1 min at 951C; 30 cycles of 1 min at 951C, 1 min at 551C, 1 min at 721C; 5 min at 721C. Primers spanning the ARE I region are forward 5 0 -TCTGCCTTTGTCCCCTAGAT-3 0 and reverse 5 0 -AACCTTCATTCCCCAGGACT-3 0 . Primers for the region upstream of ARE I without an ARE are forward 5 0 -GCTGGGTTTGATTTTGGAGGTAG-3 0 and reverse 5 0 -AG-CACAGTGAGGGAGACAGAAGTG-3 0 .
Transfection and luciferase reporter assays
LNCaP cells were transiently transfected using Lipofectin reagent (GIBCO/BRL) according to the manufacture's instruction. Briefly, luciferase reporter construct (250 ng) containing either PSA-luc or ARE 5 -luc (previously described in Lee et al., 2001) was cotransfected with 1 mg of expression vector as indicated or with pcDNA3 empty vector into LNCaP cells in six-well plates. After 24 h, cells were pretreated with casodex or Flutamide or vehicle only for 30 min before being treated with IL-8 for another 24 h and then lysed with passive lysis buffer from Promega. Luciferase assays were performed on equal amounts of protein (50 mg/sample). Luciferase activities in cell lysates were measured using the Dual Luciferase assay system (Promega, Madison, WI, USA). Renilla luciferases expression plasmid, pRL-tk, was used as an internal control for transfection efficiency. The results are presented as the fold induction, which is the relative luciferase activity (ratio of reporter luciferases/renilla luciferases) of the treated cells over that of the control cells as described previously (Lee et al., 2001 ).
Statistics
Each experiment was repeated at least twice and each data point was the average of triplicates or more. Data were analysed by the Student's t-test using Statview program version 5.1 (SAS, Cary, NC, USA) to examine the significant differences.
